Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the …

CouponFollow Extension

6%
OFF

Is Amgen Stock Still A Buy After An Unexpected Reveal Of Data?

2 weeks from now

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the …

msn.com

6%
OFF

Is Amgen Stock Still A Buy After An Unexpected Reveal Of Data?

2 weeks from now

Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially considering that the …

barchart.com

3%
OFF

Down 12.3% At One Point In A Single Trading Session, Is Amgen …

2 weeks from now

Nov 30, 2024 · Is Amgen Still a Top Dividend Stock? This Stock Just Dropped by 12% in 1 Day: Should You Buy the Dip? Is Amgen Stock Still a Buy After an Unexpected Reveal of Data?

fool.com

6%
OFF

Is Amgen Stock Still A Buy After An Unexpected Reveal Of Data?

2 weeks from now

Nov 29, 2024 · Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially …

sharewise.com

6%
OFF

Is Amgen Stock Still A Buy After An Unexpected Reveal Of Data?

2 weeks from now

Nov 29, 2024 · Shares of Amgen (NASDAQ: AMGN) are down by 6% in the last 30 days as I write this -- a larger-than-normal amount for a large pharma company's stock to fall, especially …

mitrade.com

3%
OFF

Amgen's Beating The Market -- Here's Why It's A Buy Now

2 weeks from now

Jul 1, 2022 · Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? 865%. Premium Investing …

fool.com

20%
OFF

AMGN - AMGEN Inc Stock Price And Quote - FINVIZ.com

2 weeks from now

Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? (Motley Fool) Nov-27-24 07:10AM Amgens MariTide shows up to 20% average weight loss in Phase 2 study ... Wait for …

finviz.com

5%
OFF

Amgen Stock Falls As Profit Outlook Disappoints Investors - Yahoo …

2 weeks from now

3 days ago · Amgen Inc (NASDAQ:AMGN) reported better-than-expected fourth-quarter results on Tuesday, but its shares fell 2.5% in after-hours trading as the company's profit outlook for …

yahoo.com

07%
OFF

Amgen: Multiple Strengths, But The Valuation Is A Concern

2 weeks from now

14 hours ago · Despite Amgen's rising share price, the dividend yield is still above its 5-year average of 3.07%. The forward yield is now about 3.1% after the recent price gain after …

seekingalpha.com

20%
OFF

Amgen's Stock Closes Off Lows To Avoid Worst Day In 24

2 weeks from now

Nov 27, 2024 · By Ciara Linnane . Amgen's MariTide achieves up to 20% weight loss in mid-stage trial, but analysts were expecting up to 25% . Amgen Inc.'s stock closed down 4.8% Tuesday, …

morningstar.com

3%
OFF

Where Will Amgen Be In 5 Years? - The Motley Fool

2 weeks from now

Sep 20, 2024 · Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? 910%. Premium …

fool.com

15%
OFF

Amgen Stock Has Surged. Here’s Where It’s Headed Next. - MSN

2 weeks from now

All of a sudden, Amgen stock is up 15% since late December to around $299. The next stop for the pharma’s shares could be above $340—if all goes well this year. At first, the stock’s gains ...

msn.com

3%
OFF

Is Amgen Still A Top Dividend Stock? - The Motley Fool

2 weeks from now

Dec 5, 2024 · Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? Why Amgen's Weight Loss …

fool.com

$328
OFF

Amgen Price Target Raised To $328 From $322 At Morgan Stanley

2 weeks from now

2 days ago · Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen to $328 from $322 and keeps an Equal Weight rating on the shares.Amgen posted a Q4 beat …

businessinsider.com

3%
OFF

Should You Buy This Giant Biotech Stock? | The Motley Fool

2 weeks from now

Nov 26, 2021 · Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? 915%. Premium …

fool.com

11%
OFF

Amgen Surpasses Q4 Earnings Forecasts | The Motley Fool

2 weeks from now

3 days ago · Adjusted EPS of $5.31 exceeded expectations of $5.08. Revenue rose to $9.1 billion, outpacing the estimated $8.88 billion, up 11% year over year. Free cash flow surged to …

fool.com

FAQs about Is Amgen Stock Still a Buy After an Unexpected Reveal of Data? Coupon?

Is Amgen stock a buy?

Down 12.3% at One Point in a Single Trading Session, Is Amgen Stock Still a Buy? One of Amgen's anti-obesity drug programs reported data from a trial recently. The market did not like that data. The outlook is a bit sunnier than it may seem at first. ...

Is Amgen (AMGN) a good stock to buy in October 2023?

Amgen Inc.'s AMGN, -0.11% pipeline of cancer, obesity and cardiovascular drugs is poised to deliver good news for the stock, analysts say, despite the company's recent setback with cancer drug Lumakras. There are 20 stocks on my high yield watchlist for October 2023. ...

Should you buy Amgen Inc (Amgen)?

Analysts have a consensus target price of $314.00 for Amgen Inc., indicating potential upside from the current stock price, which could attract investors seeking capital appreciation. Investors should be bearish about investing in Amgen Inc. for these reasons: ...

Is Amgen stock overvalued?

Portfolio Insight's blended fair value model, combining the P/E ratio and dividend yield, estimates a fair value of $310.33 per share. The two-model average is ~$299.37, indicating that Amgen is overvalued at the current price. ...

How much market share could Amgen take?

It’s difficult to determine how much market share Amgen could take. For argument’s sake, though, let’s say Amgen grabs $5 billion of that pie, up from current 2030 estimates for $2.9 billion in Maritide sales. That would add 5% additional revenue to the current 2030 consensus estimate of $38.7 billion in total sales. ...

Did the market like Amgen's latest clinical data update?

The market did not like that data. The outlook is a bit sunnier than it may seem at first. The market didn't appreciate Amgen 's (AMGN 1.00%) latest clinical data update, with the biopharma's shares falling more than 12% at one point on Nov. 26 from the previous day's close, though they recovered to close just 4.7% down for the day. ...